OA11595A - New pharmaceutical uses for NOS inhibitors. - Google Patents
New pharmaceutical uses for NOS inhibitors. Download PDFInfo
- Publication number
- OA11595A OA11595A OA1200100036A OA1200100036A OA11595A OA 11595 A OA11595 A OA 11595A OA 1200100036 A OA1200100036 A OA 1200100036A OA 1200100036 A OA1200100036 A OA 1200100036A OA 11595 A OA11595 A OA 11595A
- Authority
- OA
- OAPI
- Prior art keywords
- formula
- compound
- pyridin
- ylamine
- phenyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 16
- 150000001875 compounds Chemical class 0.000 claims abstract description 344
- 239000013543 active substance Substances 0.000 claims abstract description 25
- 208000002193 Pain Diseases 0.000 claims abstract description 20
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 13
- 230000000694 effects Effects 0.000 claims abstract description 8
- 208000019116 sleep disease Diseases 0.000 claims abstract description 8
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 32
- 239000000203 mixture Substances 0.000 claims description 28
- 241000124008 Mammalia Species 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 208000035475 disorder Diseases 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 230000001149 cognitive effect Effects 0.000 claims description 9
- 208000000094 Chronic Pain Diseases 0.000 claims description 8
- 208000005298 acute pain Diseases 0.000 claims description 8
- 230000001684 chronic effect Effects 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 206010027599 migraine Diseases 0.000 claims description 6
- 208000001407 Vascular Headaches Diseases 0.000 claims description 5
- 230000003533 narcotic effect Effects 0.000 claims description 5
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000018 receptor agonist Substances 0.000 claims description 4
- 229940044601 receptor agonist Drugs 0.000 claims description 4
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract description 40
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract description 40
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 abstract description 12
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 abstract description 11
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 abstract description 11
- 229960005181 morphine Drugs 0.000 abstract description 6
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 abstract description 5
- 229940127240 opiate Drugs 0.000 abstract description 5
- 229940080861 demerol Drugs 0.000 abstract description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 2
- 208000008784 apnea Diseases 0.000 abstract description 2
- 230000019771 cognition Effects 0.000 abstract description 2
- 206010022437 insomnia Diseases 0.000 abstract description 2
- 201000003631 narcolepsy Diseases 0.000 abstract description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000004084 narcotic analgesic agent Substances 0.000 abstract 1
- -1 chloro, fluoro, bromo, iodo Chemical group 0.000 description 90
- 238000006243 chemical reaction Methods 0.000 description 83
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 68
- 238000000034 method Methods 0.000 description 65
- 239000002904 solvent Substances 0.000 description 64
- 125000000217 alkyl group Chemical group 0.000 description 61
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 125000001424 substituent group Chemical group 0.000 description 56
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 46
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 46
- 238000010992 reflux Methods 0.000 description 45
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 41
- 229910052739 hydrogen Inorganic materials 0.000 description 36
- 239000001257 hydrogen Substances 0.000 description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 34
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 34
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 29
- 229910052757 nitrogen Inorganic materials 0.000 description 28
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 27
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 27
- 239000011541 reaction mixture Substances 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 229910001868 water Inorganic materials 0.000 description 24
- 230000001476 alcoholic effect Effects 0.000 description 23
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 21
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 21
- 125000003710 aryl alkyl group Chemical group 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 229940093499 ethyl acetate Drugs 0.000 description 19
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 125000001624 naphthyl group Chemical group 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 18
- 125000003282 alkyl amino group Chemical group 0.000 description 16
- 125000003118 aryl group Chemical group 0.000 description 16
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 229910052799 carbon Inorganic materials 0.000 description 14
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 14
- 125000003545 alkoxy group Chemical group 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 12
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 12
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 125000005605 benzo group Chemical group 0.000 description 12
- 150000008282 halocarbons Chemical class 0.000 description 12
- 229960003010 sodium sulfate Drugs 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 229910000029 sodium carbonate Inorganic materials 0.000 description 11
- 235000017550 sodium carbonate Nutrition 0.000 description 11
- 238000005160 1H NMR spectroscopy Methods 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 229910052763 palladium Inorganic materials 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- AJSTXXYNEIHPMD-UHFFFAOYSA-N triethyl borate Chemical compound CCOB(OCC)OCC AJSTXXYNEIHPMD-UHFFFAOYSA-N 0.000 description 10
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- 239000012280 lithium aluminium hydride Substances 0.000 description 9
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 9
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000003513 alkali Substances 0.000 description 8
- ICSNLGPSRYBMBD-UHFFFAOYSA-N alpha-aminopyridine Natural products NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 8
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 230000007062 hydrolysis Effects 0.000 description 8
- 238000006460 hydrolysis reaction Methods 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 239000003921 oil Substances 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 229940093956 potassium carbonate Drugs 0.000 description 8
- 235000011181 potassium carbonates Nutrition 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 235000011121 sodium hydroxide Nutrition 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 7
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 7
- 150000002431 hydrogen Chemical class 0.000 description 7
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 229960001866 silicon dioxide Drugs 0.000 description 7
- 229940083608 sodium hydroxide Drugs 0.000 description 7
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 7
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 7
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 6
- 125000006678 phenoxycarbonyl group Chemical group 0.000 description 6
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 229910000085 borane Inorganic materials 0.000 description 5
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 5
- 125000001246 bromo group Chemical group Br* 0.000 description 5
- 229910052792 caesium Inorganic materials 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 150000004678 hydrides Chemical class 0.000 description 5
- 150000002430 hydrocarbons Chemical class 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 125000002346 iodo group Chemical group I* 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- 230000029936 alkylation Effects 0.000 description 4
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 4
- 125000005270 trialkylamine group Chemical group 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- RHMXSUBWYGIKPK-UHFFFAOYSA-N (6-phenylmethoxy-3-tricyclo[6.2.1.02,7]undeca-2,4,6-trienyl)boronic acid Chemical compound C1=2C(C3)CCC3C=2C(B(O)O)=CC=C1OCC1=CC=CC=C1 RHMXSUBWYGIKPK-UHFFFAOYSA-N 0.000 description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229910017912 NH2OH Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 125000001979 organolithium group Chemical group 0.000 description 3
- 235000015320 potassium carbonate Nutrition 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 3
- 229960003708 sumatriptan Drugs 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- DSNKGSSXSYPWNC-UHFFFAOYSA-O triethylazanium;cyanide Chemical compound N#[C-].CC[NH+](CC)CC DSNKGSSXSYPWNC-UHFFFAOYSA-O 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- XJGMXHIRLHNXQA-UHFFFAOYSA-N 1-[4-(6-aminopyridin-2-yl)-3-propan-2-yloxyphenyl]-2-[4-(2-phenylethyl)piperazin-1-yl]ethanol Chemical compound CC(C)OC1=CC(C(O)CN2CCN(CCC=3C=CC=CC=3)CC2)=CC=C1C1=CC=CC(N)=N1 XJGMXHIRLHNXQA-UHFFFAOYSA-N 0.000 description 2
- QPUPPPPKBGBGDC-UHFFFAOYSA-N 2,2-dimethyl-n-[6-[4-(oxiran-2-yl)-2-propan-2-yloxyphenyl]pyridin-2-yl]propanamide Chemical compound CC(C)OC1=CC(C2OC2)=CC=C1C1=CC=CC(NC(=O)C(C)(C)C)=N1 QPUPPPPKBGBGDC-UHFFFAOYSA-N 0.000 description 2
- JXZYURNNBYDHOH-UHFFFAOYSA-N 2-(2,5-dimethyl-1h-pyrrol-3-yl)pyridine Chemical compound N1C(C)=CC(C=2N=CC=CC=2)=C1C JXZYURNNBYDHOH-UHFFFAOYSA-N 0.000 description 2
- SQWPRPIVUJCCHY-UHFFFAOYSA-N 2-bromo-6-(2,5-dimethyl-1h-pyrrol-3-yl)pyridine Chemical compound N1C(C)=CC(C=2N=C(Br)C=CC=2)=C1C SQWPRPIVUJCCHY-UHFFFAOYSA-N 0.000 description 2
- RGHQKFQZGLKBCF-UHFFFAOYSA-N 2-bromoethyl acetate Chemical compound CC(=O)OCCBr RGHQKFQZGLKBCF-UHFFFAOYSA-N 0.000 description 2
- ISDGWTZFJKFKMO-UHFFFAOYSA-N 2-phenyl-1,3-dioxane-4,6-dione Chemical compound O1C(=O)CC(=O)OC1C1=CC=CC=C1 ISDGWTZFJKFKMO-UHFFFAOYSA-N 0.000 description 2
- MNUHYQZBNHDABI-UHFFFAOYSA-N 3-azabicyclo[3.1.0]hexan-6-amine Chemical group C1NCC2C(N)C21 MNUHYQZBNHDABI-UHFFFAOYSA-N 0.000 description 2
- DPEUWKZJZIPZKE-OFANTOPUSA-N 330936-69-1 Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@@H](N)CCSC)C1=CC=CC=C1 DPEUWKZJZIPZKE-OFANTOPUSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 101000988651 Homo sapiens Humanin-like 1 Proteins 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 229910000086 alane Inorganic materials 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- ZHXTWWCDMUWMDI-UHFFFAOYSA-N dihydroxyboron Chemical compound O[B]O ZHXTWWCDMUWMDI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 description 2
- 229960002472 eletriptan Drugs 0.000 description 2
- 150000002081 enamines Chemical class 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000004312 hexamethylene tetramine Substances 0.000 description 2
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 2
- 102000011854 humanin Human genes 0.000 description 2
- 230000036543 hypotension Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960004011 methenamine Drugs 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- JXWKMWQBYZBTBP-UHFFFAOYSA-N n-[6-[4-(bromomethyl)-2-fluorophenyl]pyridin-2-yl]-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=CC(C=2C(=CC(CBr)=CC=2)F)=N1 JXWKMWQBYZBTBP-UHFFFAOYSA-N 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 150000003003 phosphines Chemical class 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 1
- VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 1
- HTNWPEUXFDDPFM-UHFFFAOYSA-N (4-phenylmethoxynaphthalen-1-yl)boronic acid Chemical compound C12=CC=CC=C2C(B(O)O)=CC=C1OCC1=CC=CC=C1 HTNWPEUXFDDPFM-UHFFFAOYSA-N 0.000 description 1
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 description 1
- RMGFLMXDCGQKPS-UHFFFAOYSA-N 1-(2-chloroethyl)pyrrolidine Chemical compound ClCCN1CCCC1 RMGFLMXDCGQKPS-UHFFFAOYSA-N 0.000 description 1
- LKUAPSRIYZLAAO-UHFFFAOYSA-N 1-(2-phenylethyl)piperazine Chemical compound C1CNCCN1CCC1=CC=CC=C1 LKUAPSRIYZLAAO-UHFFFAOYSA-N 0.000 description 1
- UGYPXRGQGNLWOF-UHFFFAOYSA-N 1-(ethyliminomethylideneamino)-n,n-dimethylpropan-1-amine Chemical compound CCN=C=NC(CC)N(C)C UGYPXRGQGNLWOF-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- NEJSXRLPLQPRPR-UHFFFAOYSA-N 1-[4-(6-aminopyridin-2-yl)-3-(2-methylpropoxy)phenyl]-2-[4-(2-phenylethyl)piperazin-1-yl]ethanol Chemical compound CC(C)COC1=CC(C(O)CN2CCN(CCC=3C=CC=CC=3)CC2)=CC=C1C1=CC=CC(N)=N1 NEJSXRLPLQPRPR-UHFFFAOYSA-N 0.000 description 1
- HLRIGBAUGKHTST-UHFFFAOYSA-N 1-[4-[2-[4-(6-aminopyridin-2-yl)-2-methylphenyl]ethyl]piperazin-1-yl]-2-phenylethanone Chemical compound CC1=CC(C=2N=C(N)C=CC=2)=CC=C1CCN(CC1)CCN1C(=O)CC1=CC=CC=C1 HLRIGBAUGKHTST-UHFFFAOYSA-N 0.000 description 1
- RAJHFYSTJSGKAG-UHFFFAOYSA-N 1-[4-[2-[4-(6-aminopyridin-2-yl)phenyl]ethyl]piperazin-1-yl]-2-(4-chlorophenyl)ethanone Chemical compound NC1=CC=CC(C=2C=CC(CCN3CCN(CC3)C(=O)CC=3C=CC(Cl)=CC=3)=CC=2)=N1 RAJHFYSTJSGKAG-UHFFFAOYSA-N 0.000 description 1
- LBKLIVOXVRLCCR-UHFFFAOYSA-N 1-[4-[2-[4-(6-aminopyridin-2-yl)phenyl]ethyl]piperazin-1-yl]-2-methoxyethanone Chemical compound C1CN(C(=O)COC)CCN1CCC1=CC=C(C=2N=C(N)C=CC=2)C=C1 LBKLIVOXVRLCCR-UHFFFAOYSA-N 0.000 description 1
- OGBDXFPHEQDXMH-UHFFFAOYSA-N 1-[4-[2-[4-(6-aminopyridin-2-yl)phenyl]ethyl]piperazin-1-yl]-2-phenylethanone Chemical compound NC1=CC=CC(C=2C=CC(CCN3CCN(CC3)C(=O)CC=3C=CC=CC=3)=CC=2)=N1 OGBDXFPHEQDXMH-UHFFFAOYSA-N 0.000 description 1
- NXLZELPEKOKKSV-UHFFFAOYSA-N 1-[4-[2-[4-(6-aminopyridin-2-yl)phenyl]ethyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1CCC1=CC=C(C=2N=C(N)C=CC=2)C=C1 NXLZELPEKOKKSV-UHFFFAOYSA-N 0.000 description 1
- SLFNGVGRINFJLK-UHFFFAOYSA-N 1-bromo-2-fluoro-4-methylbenzene Chemical compound CC1=CC=C(Br)C(F)=C1 SLFNGVGRINFJLK-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- JEDJZELSBSBBKI-UHFFFAOYSA-N 2-[(4-bromophenyl)methyl]piperidine Chemical compound C1=CC(Br)=CC=C1CC1NCCCC1 JEDJZELSBSBBKI-UHFFFAOYSA-N 0.000 description 1
- SGFRPINTMFASGZ-UHFFFAOYSA-N 2-[4-[2-[4-(6-aminopyridin-2-yl)-2-methoxyphenyl]ethyl]piperazin-1-yl]-1-phenylethanone Chemical compound COC1=CC(C=2N=C(N)C=CC=2)=CC=C1CCN(CC1)CCN1CC(=O)C1=CC=CC=C1 SGFRPINTMFASGZ-UHFFFAOYSA-N 0.000 description 1
- MFPJYPDCDNKIJU-UHFFFAOYSA-N 2-[4-[2-[4-(6-aminopyridin-2-yl)-2-methylphenyl]ethyl]piperazin-1-yl]-1-phenylethanol Chemical compound CC1=CC(C=2N=C(N)C=CC=2)=CC=C1CCN(CC1)CCN1CC(O)C1=CC=CC=C1 MFPJYPDCDNKIJU-UHFFFAOYSA-N 0.000 description 1
- UZPCXLXPAGFDCF-UHFFFAOYSA-N 2-[4-[2-[4-(6-aminopyridin-2-yl)-2-methylphenyl]ethyl]piperazin-1-yl]-n-propan-2-ylacetamide Chemical compound C1CN(CC(=O)NC(C)C)CCN1CCC1=CC=C(C=2N=C(N)C=CC=2)C=C1C UZPCXLXPAGFDCF-UHFFFAOYSA-N 0.000 description 1
- MZLWIQJYMYEJFP-UHFFFAOYSA-N 2-[4-[2-[4-(6-aminopyridin-2-yl)phenyl]ethyl]piperazin-1-yl]-1-(4-chlorophenyl)ethanone Chemical compound NC1=CC=CC(C=2C=CC(CCN3CCN(CC(=O)C=4C=CC(Cl)=CC=4)CC3)=CC=2)=N1 MZLWIQJYMYEJFP-UHFFFAOYSA-N 0.000 description 1
- FUYOBXOTRAXEFA-UHFFFAOYSA-N 2-[4-[2-[4-(6-aminopyridin-2-yl)phenyl]ethyl]piperazin-1-yl]-1-phenylethanone Chemical compound NC1=CC=CC(C=2C=CC(CCN3CCN(CC(=O)C=4C=CC=CC=4)CC3)=CC=2)=N1 FUYOBXOTRAXEFA-UHFFFAOYSA-N 0.000 description 1
- GJKKUWOOEFFGOH-UHFFFAOYSA-N 2-[4-[2-[4-(6-aminopyridin-2-yl)phenyl]ethyl]piperazin-1-yl]-n-propan-2-ylacetamide Chemical compound C1CN(CC(=O)NC(C)C)CCN1CCC1=CC=C(C=2N=C(N)C=CC=2)C=C1 GJKKUWOOEFFGOH-UHFFFAOYSA-N 0.000 description 1
- GFRCFUCIWJRDGM-UHFFFAOYSA-N 2-amino-1-[4-[2-[4-(6-aminopyridin-2-yl)phenyl]ethyl]piperazin-1-yl]-3-phenylpropan-1-one Chemical compound C1CN(CCC=2C=CC(=CC=2)C=2N=C(N)C=CC=2)CCN1C(=O)C(N)CC1=CC=CC=C1 GFRCFUCIWJRDGM-UHFFFAOYSA-N 0.000 description 1
- 150000003930 2-aminopyridines Chemical class 0.000 description 1
- AEKQCMMJOMDJPC-UHFFFAOYSA-N 2-bromo-6-(2,5-dimethylpyrrol-1-yl)pyridine Chemical compound CC1=CC=C(C)N1C1=CC=CC(Br)=N1 AEKQCMMJOMDJPC-UHFFFAOYSA-N 0.000 description 1
- SDTMFDGELKWGFT-UHFFFAOYSA-N 2-methylpropan-2-olate Chemical compound CC(C)(C)[O-] SDTMFDGELKWGFT-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- CSWZXBDDPYUJNA-UHFFFAOYSA-N 3-[2-[4-(6-aminopyridin-2-yl)phenyl]ethyl]-3-azabicyclo[3.1.0]hexan-6-amine Chemical compound C1C2C(N)C2CN1CCC(C=C1)=CC=C1C1=CC=CC(N)=N1 CSWZXBDDPYUJNA-UHFFFAOYSA-N 0.000 description 1
- KKWGCRIBOPNFTQ-UHFFFAOYSA-N 3-[2-[4-(6-aminopyridin-2-yl)phenyl]ethyl]-3-azabicyclo[3.2.1]octan-8-amine Chemical compound NC1C(C2)CCC1CN2CCC(C=C1)=CC=C1C1=CC=CC(N)=N1 KKWGCRIBOPNFTQ-UHFFFAOYSA-N 0.000 description 1
- PMEIIDDWZIOYKX-UHFFFAOYSA-N 3-[4-(6-aminopyridin-2-yl)-3-fluorophenyl]pyrrolidin-2-one Chemical compound NC1=CC=CC(C=2C(=CC(=CC=2)C2C(NCC2)=O)F)=N1 PMEIIDDWZIOYKX-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- YVTQRJWTWBGGRV-UHFFFAOYSA-N 6-(2-fluoro-4-pyrrolidin-3-ylphenyl)pyridin-2-amine Chemical compound NC1=CC=CC(C=2C(=CC(=CC=2)C2CNCC2)F)=N1 YVTQRJWTWBGGRV-UHFFFAOYSA-N 0.000 description 1
- HPGBMLXVPIUGOL-UHFFFAOYSA-N 6-[2-(3-methylbutoxy)-4-[2-[4-(2-phenylethyl)piperazin-1-yl]ethyl]phenyl]pyridin-2-amine Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(OCCC(C)C)=CC=1CCN(CC1)CCN1CCC1=CC=CC=C1 HPGBMLXVPIUGOL-UHFFFAOYSA-N 0.000 description 1
- VAKNGUAJSSBUAJ-UHFFFAOYSA-N 6-[2-cyclobutyloxy-4-[2-[4-(2-phenylethyl)piperazin-1-yl]ethyl]phenyl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C(=CC(CCN3CCN(CCC=4C=CC=CC=4)CC3)=CC=2)OC2CCC2)=N1 VAKNGUAJSSBUAJ-UHFFFAOYSA-N 0.000 description 1
- FVWIQFODGYGTSF-UHFFFAOYSA-N 6-[2-cyclopentyloxy-4-[2-[4-(2-phenylethyl)piperazin-1-yl]ethyl]phenyl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C(=CC(CCN3CCN(CCC=4C=CC=CC=4)CC3)=CC=2)OC2CCCC2)=N1 FVWIQFODGYGTSF-UHFFFAOYSA-N 0.000 description 1
- WUUMDSIFJSDOFP-UHFFFAOYSA-N 6-[2-cyclopropyloxy-4-[2-[4-(2-phenylethyl)piperazin-1-yl]ethyl]phenyl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C(=CC(CCN3CCN(CCC=4C=CC=CC=4)CC3)=CC=2)OC2CC2)=N1 WUUMDSIFJSDOFP-UHFFFAOYSA-N 0.000 description 1
- OKUDFFXWUFUKID-UHFFFAOYSA-N 6-[2-methyl-4-[2-[4-(2-phenylethyl)piperazin-1-yl]ethyl]phenyl]pyridin-2-amine Chemical compound C=1C=C(C=2N=C(N)C=CC=2)C(C)=CC=1CCN(CC1)CCN1CCC1=CC=CC=C1 OKUDFFXWUFUKID-UHFFFAOYSA-N 0.000 description 1
- KULJYMFZZGRXIP-UHFFFAOYSA-N 6-[4-(1-methylpyrrolidin-3-yl)oxynaphthalen-1-yl]pyridin-2-amine Chemical compound C1N(C)CCC1OC(C1=CC=CC=C11)=CC=C1C1=CC=CC(N)=N1 KULJYMFZZGRXIP-UHFFFAOYSA-N 0.000 description 1
- IHZMAFFABJBKLS-UHFFFAOYSA-N 6-[4-(2-aminocyclohexyl)oxy-5,6,7,8-tetrahydronaphthalen-1-yl]pyridin-2-amine Chemical compound NC1CCCCC1OC1=CC=C(C=2N=C(N)C=CC=2)C2=C1CCCC2 IHZMAFFABJBKLS-UHFFFAOYSA-N 0.000 description 1
- UZAQQTZLRMTWHX-UHFFFAOYSA-N 6-[4-(2-aminocyclopentyl)oxynaphthalen-1-yl]pyridin-2-amine Chemical compound NC1CCCC1OC(C1=CC=CC=C11)=CC=C1C1=CC=CC(N)=N1 UZAQQTZLRMTWHX-UHFFFAOYSA-N 0.000 description 1
- IEXLTLFFAZEUTQ-UHFFFAOYSA-N 6-[4-(2-aminoethyl)phenyl]pyridin-2-amine Chemical compound C1=CC(CCN)=CC=C1C1=CC=CC(N)=N1 IEXLTLFFAZEUTQ-UHFFFAOYSA-N 0.000 description 1
- WMYMTJPIFWLYNH-UHFFFAOYSA-N 6-[4-(2-morpholin-4-ylethoxy)-5,6,7,8-tetrahydronaphthalen-1-yl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C=3CCCCC=3C(OCCN3CCOCC3)=CC=2)=N1 WMYMTJPIFWLYNH-UHFFFAOYSA-N 0.000 description 1
- AQGVBYXBAPUOBT-UHFFFAOYSA-N 6-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C3=CC=CC=C3C(OCCN3CCOCC3)=CC=2)=N1 AQGVBYXBAPUOBT-UHFFFAOYSA-N 0.000 description 1
- ZMWHHNZCXGTSLB-UHFFFAOYSA-N 6-[4-(2-pyrrolidin-1-ylethoxy)-5,6,7,8-tetrahydronaphthalen-1-yl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C=3CCCCC=3C(OCCN3CCCC3)=CC=2)=N1 ZMWHHNZCXGTSLB-UHFFFAOYSA-N 0.000 description 1
- ZTYPBNQYAQHLGZ-UHFFFAOYSA-N 6-[4-(3-aminocyclobutyl)oxy-5,6,7,8-tetrahydronaphthalen-1-yl]pyridin-2-amine Chemical compound C1C(N)CC1OC1=CC=C(C=2N=C(N)C=CC=2)C2=C1CCCC2 ZTYPBNQYAQHLGZ-UHFFFAOYSA-N 0.000 description 1
- IUTAPLLEBRCXTE-UHFFFAOYSA-N 6-[4-(3-aminocyclohexyl)oxy-5,6,7,8-tetrahydronaphthalen-1-yl]pyridin-2-amine Chemical compound C1C(N)CCCC1OC1=CC=C(C=2N=C(N)C=CC=2)C2=C1CCCC2 IUTAPLLEBRCXTE-UHFFFAOYSA-N 0.000 description 1
- DHDIFOGKNPBEGD-UHFFFAOYSA-N 6-[4-(4-aminocyclohexyl)oxy-5,6,7,8-tetrahydronaphthalen-1-yl]pyridin-2-amine Chemical compound C1CC(N)CCC1OC1=CC=C(C=2N=C(N)C=CC=2)C2=C1CCCC2 DHDIFOGKNPBEGD-UHFFFAOYSA-N 0.000 description 1
- BDTJRQNAAHDJRB-UHFFFAOYSA-N 6-[4-(4-aminocyclohexyl)oxynaphthalen-1-yl]pyridin-2-amine Chemical compound C1CC(N)CCC1OC(C1=CC=CC=C11)=CC=C1C1=CC=CC(N)=N1 BDTJRQNAAHDJRB-UHFFFAOYSA-N 0.000 description 1
- CSGPZVMBYBXUKI-UHFFFAOYSA-N 6-[4-(piperidin-3-ylmethoxy)-5,6,7,8-tetrahydronaphthalen-1-yl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C=3CCCCC=3C(OCC3CNCCC3)=CC=2)=N1 CSGPZVMBYBXUKI-UHFFFAOYSA-N 0.000 description 1
- FQHYQQMQUKBHSL-UHFFFAOYSA-N 6-[4-[(1-methylpiperidin-3-yl)methoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]pyridin-2-amine Chemical compound C1N(C)CCCC1COC(C=1CCCCC=11)=CC=C1C1=CC=CC(N)=N1 FQHYQQMQUKBHSL-UHFFFAOYSA-N 0.000 description 1
- CPECOYSLYOHKSF-UHFFFAOYSA-N 6-[4-[2-(4-amino-2,6-dimethylpiperidin-1-yl)ethyl]phenyl]pyridin-2-amine Chemical compound CC1CC(N)CC(C)N1CCC1=CC=C(C=2N=C(N)C=CC=2)C=C1 CPECOYSLYOHKSF-UHFFFAOYSA-N 0.000 description 1
- XHLWQHUDZMTMJK-UHFFFAOYSA-N 6-[4-[2-(4-benzhydrylpiperazin-1-yl)ethyl]phenyl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C=CC(CCN3CCN(CC3)C(C=3C=CC=CC=3)C=3C=CC=CC=3)=CC=2)=N1 XHLWQHUDZMTMJK-UHFFFAOYSA-N 0.000 description 1
- INUBUGCRBWRIDX-UHFFFAOYSA-N 6-[4-[2-(4-phenylpiperidin-1-yl)ethoxy]naphthalen-1-yl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C3=CC=CC=C3C(OCCN3CCC(CC3)C=3C=CC=CC=3)=CC=2)=N1 INUBUGCRBWRIDX-UHFFFAOYSA-N 0.000 description 1
- YGTFZZXTRLPAFA-UHFFFAOYSA-N 6-[4-[2-(8-azaspiro[4.5]decan-8-yl)ethyl]phenyl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C=CC(CCN3CCC4(CCCC4)CC3)=CC=2)=N1 YGTFZZXTRLPAFA-UHFFFAOYSA-N 0.000 description 1
- CNRQNFFMXHNVBU-UHFFFAOYSA-N 6-[4-[2-(dimethylamino)ethoxy]-5,6,7,8-tetrahydronaphthalen-1-yl]pyridin-2-amine Chemical compound C1=2CCCCC=2C(OCCN(C)C)=CC=C1C1=CC=CC(N)=N1 CNRQNFFMXHNVBU-UHFFFAOYSA-N 0.000 description 1
- WPECHTREAJBIKW-UHFFFAOYSA-N 6-[4-[2-(dimethylamino)ethoxy]naphthalen-1-yl]pyridin-2-amine Chemical compound C12=CC=CC=C2C(OCCN(C)C)=CC=C1C1=CC=CC(N)=N1 WPECHTREAJBIKW-UHFFFAOYSA-N 0.000 description 1
- SWMJUPHDUXMCPT-UHFFFAOYSA-N 6-[4-[2-[4-(2-amino-2-phenylethyl)piperazin-1-yl]ethyl]phenyl]pyridin-2-amine Chemical compound C=1C=CC=CC=1C(N)CN(CC1)CCN1CCC(C=C1)=CC=C1C1=CC=CC(N)=N1 SWMJUPHDUXMCPT-UHFFFAOYSA-N 0.000 description 1
- GOZHUVSZDFEZQU-UHFFFAOYSA-N 6-[4-[2-[4-(dimethylamino)piperidin-1-yl]ethoxy]naphthalen-1-yl]pyridin-2-amine Chemical compound C1CC(N(C)C)CCN1CCOC(C1=CC=CC=C11)=CC=C1C1=CC=CC(N)=N1 GOZHUVSZDFEZQU-UHFFFAOYSA-N 0.000 description 1
- GRBNXSCQEUQDTH-UHFFFAOYSA-N 6-[4-[2-[di(propan-2-yl)amino]ethoxy]naphthalen-1-yl]pyridin-2-amine Chemical compound C12=CC=CC=C2C(OCCN(C(C)C)C(C)C)=CC=C1C1=CC=CC(N)=N1 GRBNXSCQEUQDTH-UHFFFAOYSA-N 0.000 description 1
- ULTXUNMYXMQFOT-UHFFFAOYSA-N 6-[6-(2-pyrrolidin-1-ylethoxy)-1,8,9,10,11,12-hexahydrotricyclo[6.2.2.0^{2,7}]dodeca-3,9-dien-3-yl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C=3C4CCC(CC4)C=3C(OCCN3CCCC3)=CC=2)=N1 ULTXUNMYXMQFOT-UHFFFAOYSA-N 0.000 description 1
- CMFRYOUCSMKWRW-UHFFFAOYSA-N 6-[6-[2-(dimethylamino)ethoxy]-1,8,9,10,11,12-hexahydrotricyclo[6.2.2.0^{2,7}]dodeca-3,9-dien-3-yl]pyridin-2-amine Chemical compound C1=2C(CC3)CCC3C=2C(OCCN(C)C)=CC=C1C1=CC=CC(N)=N1 CMFRYOUCSMKWRW-UHFFFAOYSA-N 0.000 description 1
- BYQRRDHFZKRLQI-UHFFFAOYSA-N 6-[7-(2-morpholin-4-ylethoxy)-2,3-dihydro-1h-inden-4-yl]pyridin-2-amine Chemical compound NC1=CC=CC(C=2C=3CCCC=3C(OCCN3CCOCC3)=CC=2)=N1 BYQRRDHFZKRLQI-UHFFFAOYSA-N 0.000 description 1
- TWGXGLHYAQFZKV-UHFFFAOYSA-N 6-[7-[2-[4-(dimethylamino)piperidin-1-yl]ethoxy]-2,3-dihydro-1h-inden-4-yl]pyridin-2-amine Chemical compound C1CC(N(C)C)CCN1CCOC1=CC=C(C=2N=C(N)C=CC=2)C2=C1CCC2 TWGXGLHYAQFZKV-UHFFFAOYSA-N 0.000 description 1
- ZACCKCZSJRFNCD-UHFFFAOYSA-N 8-[2-[4-(6-aminopyridin-2-yl)phenyl]ethyl]-3-benzyl-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound NC1=CC=CC(C=2C=CC(CCN3CCC4(CC3)C(N(CC=3C=CC=CC=3)C(=O)N4)=O)=CC=2)=N1 ZACCKCZSJRFNCD-UHFFFAOYSA-N 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101100495911 Arabidopsis thaliana CHR10 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- VEIBXGFKLHHQHY-UHFFFAOYSA-N C1CN(C)CCN1CCOC1=CC=C(C=2N=C(N)C=CC=2)C2=C1C1CCC2C1 Chemical compound C1CN(C)CCN1CCOC1=CC=C(C=2N=C(N)C=CC=2)C2=C1C1CCC2C1 VEIBXGFKLHHQHY-UHFFFAOYSA-N 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- IWRBTNUCMYRRPV-UHFFFAOYSA-N NC1=CC=CC(C=2C=3C4CCC(C4)C=3C(OCCN3CCCC3)=CC=2)=N1 Chemical compound NC1=CC=CC(C=2C=3C4CCC(C4)C=3C(OCCN3CCCC3)=CC=2)=N1 IWRBTNUCMYRRPV-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- DZJXKISLUDYJSV-UHFFFAOYSA-N [N].C1CCNC1 Chemical compound [N].C1CCNC1 DZJXKISLUDYJSV-UHFFFAOYSA-N 0.000 description 1
- GPWHDDKQSYOYBF-UHFFFAOYSA-N ac1l2u0q Chemical compound Br[Br-]Br GPWHDDKQSYOYBF-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000003502 anti-nociceptive effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000005604 azodicarboxylate group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- JJGAHPCJQQSLTL-UHFFFAOYSA-N bicyclo[3.1.0]hexan-6-amine Chemical group C1CCC2C(N)C21 JJGAHPCJQQSLTL-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- TXHKKANZSDSWIS-UHFFFAOYSA-N chembl39005 Chemical compound C1=2C(C3)CCC3C=2C(OCCN(C)C)=CC=C1C1=CC=CC(N)=N1 TXHKKANZSDSWIS-UHFFFAOYSA-N 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000007819 coupling partner Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- HHQJWDKIRXRTLS-UHFFFAOYSA-N n'-bromobutanediamide Chemical compound NC(=O)CCC(=O)NBr HHQJWDKIRXRTLS-UHFFFAOYSA-N 0.000 description 1
- OZYPPHLDZUUCCI-UHFFFAOYSA-N n-(6-bromopyridin-2-yl)-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=CC(Br)=N1 OZYPPHLDZUUCCI-UHFFFAOYSA-N 0.000 description 1
- VSJNBRHKFISDKH-UHFFFAOYSA-N n-[6-(2-fluoro-4-formylphenyl)pyridin-2-yl]-2,2-dimethylpropanamide Chemical compound CC(C)(C)C(=O)NC1=CC=CC(C=2C(=CC(C=O)=CC=2)F)=N1 VSJNBRHKFISDKH-UHFFFAOYSA-N 0.000 description 1
- JXTLYBKAQQBEGK-UHFFFAOYSA-N n-[6-(4-formyl-2-propan-2-yloxyphenyl)pyridin-2-yl]-2,2-dimethylpropanamide Chemical compound CC(C)OC1=CC(C=O)=CC=C1C1=CC=CC(NC(=O)C(C)(C)C)=N1 JXTLYBKAQQBEGK-UHFFFAOYSA-N 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- JASMWYNKLTULAN-UHFFFAOYSA-N octan-3-amine Chemical compound CCCCCC(N)CC JASMWYNKLTULAN-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008203 oral pharmaceutical composition Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- RZXMPPFPUUCRFN-UHFFFAOYSA-N p-toluidine Chemical compound CC1=CC=C(N)C=C1 RZXMPPFPUUCRFN-UHFFFAOYSA-N 0.000 description 1
- 229910003445 palladium oxide Inorganic materials 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- JQPTYAILLJKUCY-UHFFFAOYSA-N palladium(ii) oxide Chemical compound [O-2].[Pd+2] JQPTYAILLJKUCY-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- JAKNYTQAGPEFJB-UHFFFAOYSA-N piperidin-2-amine Chemical group NC1CCCCN1 JAKNYTQAGPEFJB-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- KWQRKOSMSFLBTJ-UHFFFAOYSA-N tert-butyl 3-methylsulfonyloxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(C)(=O)=O)C1 KWQRKOSMSFLBTJ-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- SFLXUZPXEWWQNH-UHFFFAOYSA-K tetrabutylazanium;tribromide Chemical compound [Br-].[Br-].[Br-].CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC.CCCC[N+](CCCC)(CCCC)CCCC SFLXUZPXEWWQNH-UHFFFAOYSA-K 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
- VFJYIHQDILEQNR-UHFFFAOYSA-M trimethylsulfanium;iodide Chemical compound [I-].C[S+](C)C VFJYIHQDILEQNR-UHFFFAOYSA-M 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9615298P | 1998-08-11 | 1998-08-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA11595A true OA11595A (en) | 2004-08-19 |
Family
ID=22255853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200100036A OA11595A (en) | 1998-08-11 | 1999-08-05 | New pharmaceutical uses for NOS inhibitors. |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US20020151572A1 (fr) |
| EP (1) | EP1109556A2 (fr) |
| JP (1) | JP2002522498A (fr) |
| KR (1) | KR20010085364A (fr) |
| CN (1) | CN1323211A (fr) |
| AP (1) | AP2001002067A0 (fr) |
| AR (1) | AR020009A1 (fr) |
| AU (1) | AU749439B2 (fr) |
| BR (1) | BR9912906A (fr) |
| CA (1) | CA2340200A1 (fr) |
| CO (1) | CO5130011A1 (fr) |
| CR (1) | CR6302A (fr) |
| CZ (1) | CZ2001486A3 (fr) |
| DZ (1) | DZ2867A1 (fr) |
| EA (1) | EA200100125A1 (fr) |
| EE (1) | EE200100084A (fr) |
| GE (1) | GEP20043252B (fr) |
| GT (1) | GT199900127A (fr) |
| HK (1) | HK1041819A1 (fr) |
| HR (1) | HRP20010099A2 (fr) |
| HU (1) | HUP0103113A3 (fr) |
| ID (1) | ID28227A (fr) |
| IL (1) | IL141031A0 (fr) |
| IS (1) | IS5814A (fr) |
| MA (1) | MA26670A1 (fr) |
| NO (1) | NO20010685L (fr) |
| NZ (1) | NZ509298A (fr) |
| OA (1) | OA11595A (fr) |
| PA (1) | PA8479801A1 (fr) |
| PE (1) | PE20001025A1 (fr) |
| PL (1) | PL346842A1 (fr) |
| SK (1) | SK1702001A3 (fr) |
| SV (1) | SV1999000121A (fr) |
| TN (1) | TNSN99154A1 (fr) |
| TR (3) | TR200401803T2 (fr) |
| WO (1) | WO2000009130A2 (fr) |
| YU (1) | YU9601A (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010049379A1 (en) | 1997-08-27 | 2001-12-06 | Lowe John Adams | 2-aminopyridines containing fused ring substituents |
| EP1267862A2 (fr) | 2000-02-22 | 2003-01-02 | Cellegy Canada Inc. | Methodes et compositions destinees a ameliorer la qualite du sommeil |
| CN100430399C (zh) * | 2002-03-20 | 2008-11-05 | 昆士兰大学 | 包含一氧化氮供体和阿片样物质止痛剂的组合物和方法 |
| WO2005007627A1 (fr) * | 2003-07-18 | 2005-01-27 | Nihon Nohyaku Co., Ltd. | Derive de phenylpyridine, produit intermediaire correspondant, et herbicide contenant ledit derive de phenylpyridine en tant qu'ingredient actif |
| US9120750B2 (en) | 2013-03-07 | 2015-09-01 | Northwestern University | 2-Aminopyridine-based selective neuronal nitric oxide synthase inhibitors |
| US10759791B2 (en) | 2014-11-04 | 2020-09-01 | Northwestern University | Mammalian and bacterial nitric oxide synthase inhibitors |
| WO2016073623A2 (fr) | 2014-11-04 | 2016-05-12 | Northwestern University | Inhibiteurs d'oxyde nitrique synthase d'origine bactérienne et mammalienne |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ291647B6 (cs) * | 1996-03-29 | 2003-04-16 | Pfizer Inc. | 6-Fenylpyridyl-2-aminové deriváty, jejich použití a farmaceutické kompozice na jejich bázi |
| HN1997000027A (es) * | 1996-12-06 | 1997-06-05 | Pfizer Prod Inc | Derivados de 6-fenil piridil - 2 amina |
| YU35699A (sh) * | 1997-02-10 | 2002-06-19 | Pfizer Products Inc. | 2-amino-6-(2-supstituisan-4-fenoksi)-supstituisani piridini |
| HN1998000118A (es) * | 1997-08-27 | 1999-02-09 | Pfizer Prod Inc | 2 - aminopiridinas que contienen sustituyentes de anillos condensados. |
| HN1998000125A (es) * | 1997-08-28 | 1999-02-09 | Pfizer Prod Inc | 2-aminopiridinas con sustituyentes alcoxi ramificados |
| SE9703693D0 (sv) * | 1997-10-10 | 1997-10-10 | Astra Pharma Prod | Novel combination |
-
1999
- 1999-08-05 BR BR9912906-0A patent/BR9912906A/pt not_active IP Right Cessation
- 1999-08-05 EP EP99933077A patent/EP1109556A2/fr not_active Withdrawn
- 1999-08-05 KR KR1020017001788A patent/KR20010085364A/ko not_active Application Discontinuation
- 1999-08-05 EA EA200100125A patent/EA200100125A1/ru unknown
- 1999-08-05 JP JP2000564633A patent/JP2002522498A/ja active Pending
- 1999-08-05 CZ CZ2001486A patent/CZ2001486A3/cs unknown
- 1999-08-05 HU HU0103113A patent/HUP0103113A3/hu unknown
- 1999-08-05 CA CA002340200A patent/CA2340200A1/fr not_active Abandoned
- 1999-08-05 CN CN99811907A patent/CN1323211A/zh active Pending
- 1999-08-05 TR TR2004/01803T patent/TR200401803T2/xx unknown
- 1999-08-05 YU YU9601A patent/YU9601A/sh unknown
- 1999-08-05 TR TR2001/03661T patent/TR200103661T2/xx unknown
- 1999-08-05 AU AU49248/99A patent/AU749439B2/en not_active Ceased
- 1999-08-05 NZ NZ509298A patent/NZ509298A/en unknown
- 1999-08-05 OA OA1200100036A patent/OA11595A/en unknown
- 1999-08-05 AP APAP/P/2001/002067A patent/AP2001002067A0/en unknown
- 1999-08-05 TR TR2001/00434T patent/TR200100434T2/xx unknown
- 1999-08-05 WO PCT/IB1999/001389 patent/WO2000009130A2/fr not_active Application Discontinuation
- 1999-08-05 GE GEAP19995742A patent/GEP20043252B/en unknown
- 1999-08-05 EE EEP200100084A patent/EE200100084A/xx unknown
- 1999-08-05 PL PL99346842A patent/PL346842A1/xx not_active Application Discontinuation
- 1999-08-05 SK SK170-2001A patent/SK1702001A3/sk unknown
- 1999-08-05 IL IL14103199A patent/IL141031A0/xx unknown
- 1999-08-05 ID IDW20010317A patent/ID28227A/id unknown
- 1999-08-06 PA PA19998479801A patent/PA8479801A1/es unknown
- 1999-08-09 GT GT199900127A patent/GT199900127A/es unknown
- 1999-08-09 PE PE1999000801A patent/PE20001025A1/es not_active Application Discontinuation
- 1999-08-10 SV SV1999000121A patent/SV1999000121A/es not_active Application Discontinuation
- 1999-08-10 TN TNTNSN99154A patent/TNSN99154A1/fr unknown
- 1999-08-10 AR ARP990103995A patent/AR020009A1/es unknown
- 1999-08-10 DZ DZ990167A patent/DZ2867A1/fr active
- 1999-08-10 MA MA25724A patent/MA26670A1/fr unknown
- 1999-08-11 US US09/372,352 patent/US20020151572A1/en not_active Abandoned
- 1999-08-11 CO CO99051077A patent/CO5130011A1/es unknown
-
2001
- 2001-01-16 IS IS5814A patent/IS5814A/is unknown
- 2001-02-06 CR CR6302A patent/CR6302A/es not_active Application Discontinuation
- 2001-02-08 HR HR20010099A patent/HRP20010099A2/hr not_active Application Discontinuation
- 2001-02-09 NO NO20010685A patent/NO20010685L/no not_active Application Discontinuation
-
2002
- 2002-05-13 HK HK02103597.9A patent/HK1041819A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3411271B2 (ja) | Ｎｏｓ阻害剤であり縮合環置換基を含む２−アミノピリジン類 | |
| EP1471055A1 (fr) | Dérivés de 6-phenylpyridyl-2-amines | |
| OA11123A (en) | 6-Phenylpyridyl-2-amine derivatives useful as nos inhibitors | |
| EP1007512B1 (fr) | 2-aminopyridines alcoxy-substituees ramifiees, utilisees comme inhibiteurs de nos | |
| OA11943A (en) | New pharmacetical combinations for nos inhibitors | |
| OA11595A (en) | New pharmaceutical uses for NOS inhibitors. | |
| US20040229911A1 (en) | New pharmaceutical combinations for NOS inhibitors | |
| EP1084109B1 (fr) | 2-aminopyridines contenant des substituants a anneaux condenses et convenant comme inhibiteurs de synthase de l'oxyde nitrique | |
| US20010049379A1 (en) | 2-aminopyridines containing fused ring substituents | |
| MXPA01001548A (en) | New pharmaceutical uses for nos inhibitors | |
| EP4367123A1 (fr) | Composés de pyrimidine destinés à être utilisés en tant qu'inhibiteurs de map4k1 | |
| MXPA98004050A (en) | Derivatives of pirido (2,3-d) pyrimidine and pharmaceutical compositions of mis |